covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Diagnóstico del retraso del crecimiento
Información de la revista
Vol. 50. Núm. 6.
Páginas 216-236 (junio 2003)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 50. Núm. 6.
Páginas 216-236 (junio 2003)
Acceso a texto completo
Diagnóstico del retraso del crecimiento
Diagnosis of growth retardation
Visitas
27830
L. Castro-Feijoo, M. Pombo
Autor para correspondencia
pdmapoar@usc.es

Correspondencia: Prof. M. Pombo. Unidad de Endocrinología, Crecimiento y Adolescencia. Hospital Clínico Universitario de Santiago de Compostela. USC. A Choupana, s/n. Santiago de Compostela. 15706 A Coruña. España.
Unidad de Endocrinología, Crecimiento y Adolescencia. Departamento de Pediatría. Hospital Clínico Universitario de Santiago de Compostela. Universidad de Santiago de Compostela. Santiago de Compostela. España
Este artículo ha recibido
Información del artículo

El crecimiento es un proceso biológico complejo, producto de la interacción entre múltiples factores endógenos (genéticos, hormonales, metabólicos, receptividad de los tejidos diana) y factores exógenos (nutrición, actividad física e influencias psicosociales). Es uno de los indicadores más sensibles del estado de salud del niño, de su nutrición y de sus antecedentes genéticos. Las desviaciones de la normalidad pueden ser la primera manifestación de una patología subyacente congénita o adquirida, por lo que se necesita disponer de una correcta comprensión del proceso del crecimiento y de los diferentes trastornos que pueden alterarlo. Entendemos por talla baja aquella en la que un individuo se encuentra por debajo de – 2 desviaciones estándar, para una determinada edad y sexo, en relación con la media poblacional. Actualmente, la clasificamos en talla baja idiopática y talla baja patológica. El diagnóstico continúa basándose en la correcta interpretación de la anamnesis y de la exploración física, aun cuando la historia reciente de la endocrinología se ha caracterizado por un emergente desarrollo de los métodos diagnósticos. Entre ellos destacan los avances en genética molecular, que han permitido la localización y caracterización en el ser humano de los genes que codifican proteínas implicadas en la regulación hormonal del crecimiento, como GH, POU1F1, PROP 1, Hex1, rGHRH, rGH, IGF-1, LHX3, LHX4, etc. Esta área constituye una de nuestras principales líneas de investigación y en esta revisión aportaremos algunos resultados, entre ellos el hallazgo de una nueva mutación (MiL) en un paciente con síndrome de Laron.

Growth is a complex biological process resulting from the interplay between multiple endogenous factors such as genetics, hormones and metabolism as well as exogenous factors such as nutrition, physical activity and psychosocial status. Growth is one of the most sensitive markers of children's health, nutritional status, and genetic background. Deviation from normality may be the first manifestation of an underlying congenital or acquired disorder. Thus, it is important to understand the growth process and the various disorders that can disturb it. Short stature is defined as a condition in which the height of an individual is 2 SD below the corresponding mean height for a given age, sex, and population group. Currently, short stature is classified into idiopathic and pathological. Despite the development of different diagnostic methods, diagnosis is still based on accurate interpretation of the patient's history and physical examination, even though the development of diagnostic methods in endocrinology has recently increased. Among these, advances in molecular genetics can be emphasized. These advances have allowed localization and characterization of the genes codifying hormonal regulation of growth such as GH, POU1F1, PROP 1, Hex 1, GHRHR, GHR, IGF-1, LHX3, LHX4, etc. This field constitutes a major line of inquiry. In this review we discuss some of the results, among them the discovery of a new mutation (MiL) in a patient with Laron syndrome.

Palabras clave:
Crecimiento
Talla baja
Clasificación
Diagnóstico
GH
RGH
POU1F1
PROP1
Ghrelin
Key words:
Growth
Short stature
Classification
Diagnosis
GH
GHR
POU1F1-PROP1
Ghrelin
El Texto completo está disponible en PDF
Bibliografía
[1.]
R. Yturriaga.
Semiología clínica del crecimiento: talla baja idiopática. En Sociedad Española de Endocrinología Pediátrica.
pp. 3-22
[2.]
M. Hernández Rodríguez.
El patrón de crecimiento humano y su evaluación.
Tratado de endocrinología pediátrica, pp. 244-274
[3.]
F. Cassorla, X. Gaete.
Clasificación y valoración de la talla baja.
Tratado de endocrinología pediátrica, pp. 275-289
[4.]
M. Pombo, F. Rodríguez Hierro, R. Castro-Pereira.
Patología de la hipófisis.
Tratado de Pediatría, pp. 870-885
[5.]
P.C. Sizonenko, P.E. Clayton, P. Cohen, R.L. Hintz, T. Tanaka, Z. Laron.
Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 1: diagnosis of growth hormone deficiency.
Growth Horm IGF Res, 11 (2001), pp. 137-165
[6.]
L. Castro-Feijoo, M. Pombo Arias.
Pruebas bioquímicas.
Hormona y factores de crecimiento, 5 (2002), pp. 36-43
[7.]
J. Argente, S.A. Abusrewil, G. Bona, F. Chiarelli, C.J. Kelnar, N. Skordis.
International Workshop on Management of Puberty for Optimum Auxological Results. Isolated growth hormone deficiency in children and adolescents.
J Pediatr Endocrinol Metab, 14 (2001), pp. 1003-1008
[8.]
J. Argente, L.A. Pérez Jurado, J. Sotos.
Bases moleculares de la patología del crecimiento.
Rev Esp Pediatr, 56 (2000), pp. 94-118
[9.]
C. Diéguez, L. Pinilla, E. Aguilar.
Integración neuroendocrina y regulación de la secreción hormonal hipofisaria.
Tratado de endocrinología pediátrica, pp. 43-83
[10.]
L.E. Cohen, S. Radovick.
Molecular basis of combined pituitary hormone deficiencies.
Endocr Rev, 23 (2002), pp. 431-442
[11.]
C. Quinteiro García, L. Castro-Feijoo, L. Loidi Fernández de Trocóniz, J. Barreiro Conde, J. Fernández Toral, F. Domínguez Puente, et al.
Patología molecular a nivel del eje de la hormona de crecimiento.
Avances en pediatría X. A, pp. 11-31
[12.]
M. Pombo.
Retrasos de crecimiento.
Monografías de pediatría,
[13.]
M. Ciaccio, M.A. Rivarola, A. Belgorosky.
Talla baja idiopática.
Tratado de endocrinología pediátrica, pp. 283-289
[14.]
M. Pombo, P. Mosteiro, J. Barreiro, C. Quinteiro, J.R. Castro, J.M. Pérez-Gallego, et al.
Etiopatogenia y tratamiento de la talla baja idiopática.
Hormona y factores crecimiento, 3 (1998), pp. 44-52
[15.]
M.B. Ranke.
Towards a consensus on the definition of idiopathic short stature.
Horm Res, 45 (1996), pp. 64-66
[16.]
A.M. Pasquino, A. Albanese, M. Bozzola, G.E. Butler, F. Buzi, V. Cherubini, et al.
International Workshop on Management of Puberty for Optimum Auxological Results. Idiopathic short stature.
J Pediatr Endocrinol Metab, 14 (2001), pp. 967-974
[17.]
R.M. Ayling, R. Ross, P. Towner, S. Von Laue, J. Finidori, S. Moutoussamy, et al.
A dominant-negative mutation of the growth hormone receptor causes familial short stature.
Nat Genet, 16 (1997), pp. 13-14
[18.]
A. Goddard, R. Covello, S.M. Luoh, T. Clackson, K. Attie, N. Gesundheit, et al.
Mutations of the growth hormone receptor in children with idiopathic short stature.
N Engl J Med, 333 (1995), pp. 1094-1098
[19.]
A.D. Goddard, P. Dowd, S. Chernausek, M. Geffner, J. Gertner, R. Hintz, et al.
Partial growth-hormone insentivity: the role of growth-hormone receptor mutations in idiopatic short stature.
J Pediatr, 131 (1997), pp. 551-555
[20.]
A.D. Goddard, P. Dowd, S. Chernausek, M. Geffner, J. Gertner, R. Hintz, et al.
Partial growth-hormone insentivity: the role of growth-hormone receptor mutations in idiopatic short stature.
J Pediatr, 131 (1997), pp. 551-555
[21.]
J.E. Sánchez, E. Perera, L. Baumbach, W.W. Cleveland.
Growth hormone receptor mutations in children with idiopathic short stature.
J Clin Endocrinol Metab, 83 (1998), pp. 4079-4083
[22.]
P.J. Godowski, D.W. Leung, L.R. Meacham, J.P. Galgani, R. Hellmiss, R. Keret, et al.
Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism.
Proc Natl Acad Sci U S A, 86 (1989), pp. 8083-8087
[23.]
L.B. Johnston, F. Pashankar, C. Camacho-Hubner, M.O. Savage, A.J. Clark.
Analysis of the intracellular signalling domain of the human growth hormone receptor in children with idiopathic short stature.
Clin Endocrinol (Oxf), 52 (2000), pp. 463-469
[24.]
P.E. Clayton, J.S. Freeth, A.J. Whatmore, R.M. Ayling, M.R. Norman, C.M. Silva.
Signal transduction defects in growth hormone insensitivity.
Acta Paediatr Suppl, 88 (1999), pp. 174-178
[25.]
K. Pearce, J. Wells.
Activation of the human growth hormone receptor.
Human growth hormone, pp. 131-143
[26.]
E. Rao, B. Weiss, M. Fukami, A. Rump, B. Niesler, A. Mertz, et al.
Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome.
Nature Genet, 16 (1997), pp. 54-63
[27.]
G. Binder, C.P. Schwarzecp, M.B. Ranke.
Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone.
J Clin Endocrinol Metab, 85 (2000), pp. 245-249
[28.]
K.M. Attie.
Genetic studies in idiopathic short stature.
Curr Opin Pediatr, 12 (2000), pp. 400-404
[29.]
G.A. Rappold, M. Fukami, B. Niesler, S. Schiller, W. Zumkeller, M. Bettendorf, et al.
Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature.
J Clin Endocrinol Metab, 87 (2002), pp. 1402-1406
[30.]
S. Bernasconi, S. Mariani, C. Falcinelli, S. Milioli, L. Iughetti, A. Forabosco.
SHOX gene in Leri-Weill syndrome and in idiopathic short stature.
J Endocrinol Invest, 24 (2001), pp. 737-741
[31.]
Y. Takahashi, H. Kaji, Y. Okimura, K. Goji, H. Abe, K. Chihara.
Brief report: Short stature caused by a mutant growth hormone.
N Engl J Med, 334 (1996), pp. 432-436
[32.]
J.M. Garagorri.
Retraso del crecimiento intrauterino.
Tratado de endocrinología pediátrica, pp. 312-336
[33.]
A.C.S. Hokken-Koelega, M.A.J. de Ridder, R.J. Lemmen, H. Den Hartog.
de Muinck Keizer-Schrama SMPF, Drop SLS Children born small for gestational age: do they cath up?.
Pediatr Res, 38 (1995), pp. 267-271
[34.]
J. Karlberg, K. Albertsson-Wikland.
Growth in full-term smallfor-gestational-age infants: from birth to final height.
Pediatr Res, 38 (1995), pp. 733-739
[35.]
T. Sas, P. Mulder, A. Hokken-Koelega.
Body composition, blood pressure, and lipid metabolism begore and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency.
J Clin Endocrinol Metab, 85 (2000), pp. 3786-3792
[36.]
T. Sas, P. Mulder, H.J. Aanstool, M. Houdjk, M. Jansen, M. Reeser, et al.
Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age.
Clin Endocrinol, 54 (2001), pp. 243-251
[37.]
K.A. Woods, C. Camacho-Hübner, M.O. Savage, A.J.L. Clark.
Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene.
N Engl J Med, 335 (1996), pp. 1363-1367
[38.]
N. Arends, L. Johnston, A. Hokken-Koelega, C. van Duijn, M. de Ridder, M. Savage, et al.
Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA).
J Clin Endocrinol Metab, 87 (2002), pp. 2720
[39.]
E. Schollen, G. Matthijs, M. Gewillig, J.P. Fryns, E. Legius.
PTPN11 mutation in a large family with Noonan syndrome and dizygous twinning.
Eur J Hum Genet, 11 (2003), pp. 85-88
[40.]
L. Castro-Feijoo, J. Barreiro Conde, M. Pombo Arias.
Aspectos clínicos.
El síndrome de Turner Enfoque multidisciplinario y optimización del tratamientocon GH, pp. 9-17
[41.]
M.P. Guarneri, S.A. Abusrewil, S. Bernasconi, G. Bona, L. Cavallo, A. Cicognani, et al.
International Workshop on Management of Puberty for Optimum Auxological Results. Turner's syndrome.
J Pediatr Endocrinol Metab, 14 (2001), pp. 959-965
[42.]
C. Bergadá.
Retraso del crecimiento de causa psicosocial.
Tratado de endocrinología pediátrica, pp. 307-311
[43.]
C.J. Del Valle Núñez, A.L. Gómez-Gila.
Hipocrecimiento de origen nutricional y por enfermedades crónicas.
Tratado de endocrinología pediátrica, pp. 290-306
[44.]
A. Fasano.
Celiac disease: the past, the present, the future.
Pediatrics, 107 (2001), pp. 768-770
[45.]
P. Collin, K. Kaukinen, M. Valimaki, J. Salmi.
Endocrinological disorders and celiac disease.
Endocr Rev, 23 (2002), pp. 464-483
[46.]
J.I. Labarta, E. Bello, E. León, C. Rueda, C. Labena, M. Ruiz Echarri, et al.
Valoración auxológica del hipocrecimiento.
Hormona y factores de crecimiento, 5 (2002), pp. 36-43
[47.]
E. Wuhl, F. Schaefer.
Effects of growth hormone in patients with chronic renal failure: experience in children and adults.
Horm Res, 58 (2002), pp. 35-38
[48.]
J.H. Kelnar, M.O. Savage, H.F. Stirling, P. Saenger.
Growth disorders. pathophysiology and treatment.
[49.]
J. Argente, A. Carrascosa, R. Gracía, F. Rodríguez-Hierro.
Tratado de endocrinología pediátrica y de la adolescencia.
[50.]
S. Bernasconi, T. Arrigo, M. Wasnieswsk, L. Ghizzoni, C. Ruggeri, G. Di Pasquale, et al.
Long-term results with growth hormone therapy in idiopathic hypopituitarism.
Horm Res, 53 (2000), pp. 55-59
[51.]
R. Cañete Estrada.
Déficit de hormona de crecimiento.
Tratado de endocrinología pediátrica, pp. 410-431
[52.]
M. Pombo, C.M. Pombo, A. García, E. Caminos, O. Gualillo, C.V. Álvarez, et al.
Hormonal control of growth hormone secretion.
Horm Res, 55 (2001), pp. 11-16
[53.]
Z. Laron.
Laron syndrome-primary growth hormone resistance.
Contemporary endocrinology: hormone resistance syndromes, pp. 17-37
[54.]
M. Bueno, M. Bueno-Lozano, A.L. Bueno.
Osteocondrodisplasias.
Tratado de endocrinología pediátrica, pp. 337-354
[55.]
A. Gómez-Pan, J. Rodríguez-Arnao.
Evaluación de la función hipofisaria.
Tratado de endocrinología básica y clínica. Vol.1, pp. 192-206
[56.]
P.A. Gruppuso.
The clinical laboratory evaluation of GH responsiveness.
J Clin Endocrinol Metab, 87 (2002), pp. 466-468
[57.]
Growth Hormone Research Society.
Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society.
J Clin Endocrinol Metab, 85 (2000), pp. 3990-3993
[58.]
S.M. Shalet, A. Toogood, A. Rahim, B.M. Brennan.
The diagnosis of growth hormone deficiency in children and adults.
Endocr Rev, 19 (1998), pp. 203-223
[59.]
J. Argente.
Exploracion hipotalamo-hipofisaria: secrecion de GH y prolactina. En: Sociedad Espanola de Endocrinologia Pediatrica, editor. Exploraciones funcionales en endocrinologia pediatrica.
pp. 1-47
[60.]
S.M. Shalet, A. Toogood, A. Rahim, B.M. Brennan.
The diagnosis of growth hormone deficiency in children and adults.
Endocr Rev, 19 (1998), pp. 203-223
[61.]
T. Strachan, A. Read.
Molecular patology.
Human molecular genetic, pp. 433-460
[62.]
M.G. Osorio, P. Kopp, A.C. Latronico, B.B. Mendoca, I.J. Arnhold.
Combined pituitary deficiency caused by a novel mutation of a highly conserved residue (F88S) in homeodomain of PROP-1.
J Clin Endocrinol Metab, 85 (2000), pp. 2779-2785
[63.]
C. Fluck, J. Deladoey, K. Rutishauser, A. Eble, U. Marti, W. Wu, et al.
Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP-1 gene mutation resulting in the sustitution of Arg → Cys at codon 120 (R120C).
J Clin Endocrinol Metab, 83 (1998), pp. 3727-3734
[64.]
O. Fofanova, N. Takamura, E. Kinoshita, J.S. Parks, M.R. Brown, V.A. Peterkova, et al.
Compound heterozyous deletion of the PROP-1 gene in children with combined pituitary hormone deficiency.
J Clin Endocrinol Metab, 83 (1998), pp. 2601-2604
[65.]
H. Frisch, C. Kim, G. Hausler, R. Pfaffle.
Combined pituitary hormone deficiency and pituitary hipoplasia due to a mutation of the Pit-1 gene.
Clin Endocrinology, 52 (2000), pp. 661-665
[66.]
I. Pellegrini-Bouiller, P. Belicar, A. Barlier, G. Gunz, J.P. Charvet, P. Jaquet, et al.
A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency.
J Clin Endocrinol Metab, 81 (1996), pp. 2790-2796
[67.]
S. Vallette-Kasic, I. Pellegrini-Bouiller, F. Sampieri, G. Gunz, A. Diaz, S. Radovick, et al.
Combined pituitary hormone deficiency due to the F135C human Pit-1 (Pituitary-Specific Factor I) gene mutation: functional and structural correlates.
Mol Endocrinol, 15 (2001), pp. 411-420
[68.]
S. Radovick, M. Nations, Y. Du, L.A. Berg, B.D. Weintraub, F.E. Wondisford.
A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency.
Science, 257 (1992), pp. 1115-1118
[69.]
L.A. Di Meglio, P. Hofman, P.P. Hirsch.
Molecular defects of the growth hormone axis.
Human growth hormone, pp. 169-190
[70.]
A.M. Procter, J.A. Phillips, D.N. Cooper.
The molecular genetics of growth hormone deficiency.
Hum Genet, 103 (1998), pp. 255-272
[71.]
J.K. Wagner, A. Eble, P.C. Hindmarsh, P.E. Mullis.
Prevalence of human GH-1 alterations in patiens with isolated growth hormone deficiency.
Pediatr Res, 43 (1998), pp. 105-110
[72.]
L.A. Perez Jurado, J. Argente, V. Barrios, J. Pozo, M.T. Munoz, M. Hernandez, et al.
Molecular diagnosis and endocrine evaluation of a patient with homozygous 7.0 kb deletion of the growth hormone (GH) gene Cluster: Response to biosynthetic GH terapy.
J Paediatr Endocrinol Metab, 10 (1997), pp. 185-190
[73.]
C. Quinteiro, L. Castro, L. Loidi, M. De la Fuente, J. Barreiro, M. Pombo.
Patient of isolated growth hormone deficiency shows a gene conversion between GH1 and GH2 genes.
Horm Res, 53 (2000), pp. 40
[74.]
Y. Hasegawa, K. Fujic, M. Yamada, Y. Igarashi, K. Tachibana, T. Tanaka, et al.
Identification of novel human GH1 gene polymorphisms that are associated with growth hormone secretion and height.
J Clin Endocrinol Metab, 85 (2000), pp. 1290-1295
[75.]
K. Pearce, J. Wells.
Activation of the human growth hormone receptor.
Human growth hormone, pp. 131-143
[76.]
O. Vasconez, J. Guevara Aguirre.
Deficiencia del receptor de hormona de crecimiento (GHRD). Diagnostico y tratamiento.
Tratado de endocrinologia pediatrica, pp. 437-457
[77.]
J. Guevara, A.L. Rosenbloom, R.G. Rosenfeld.
Sindromes de insensibilidad periferica a la hormona de crecimiento.
Tratado de endocrinologia pediatrica y de la adolescencia Ed, pp. 183-200
[78.]
L.B. Johnston, M.O. Savage.
Partial growth hormone insensitivity.
J Pediatr Endocrinol Metab, 12 (1999), pp. 251-257
[79.]
C. Quinteiro, L. Castro-Feijoo, L. Loidi, J. Barreiro, M. de la Fuente, F. Dominguez, et al.
Novel mutation involving the translation initiation codon of the growth hormone receptor gene (GHR) in a patient with Laron syndrome.
J Pediatr Endocrinol Metab, 15 (2002), pp. 1041-1045
[80.]
C. Quinteiro, L. Loidi, F. Dominguez, J. Barreiro, M. Pombo.
A novel mutation affecting the first methionine of the growth hormone receptor in a patient with GH insensitivity syndrome.
Horm Res, 51 (1999), pp. 46
[81.]
L. Castro, J. Barreiro, C. Quinteiro, F. Dominguez, L. Loidi, M. Pombo.
Identificacion de una mutacion en el receptor de GH en el sindrome de Costello. En: Sociedad Espanola de Endocrinologia Pediatrica.
pp. 191
[82.]
R. Castro, J. Barreiro, C. Quinteiro, F. Dominguez, L. Loidi, M. Pombo.
Identification of GHR mutation in Costello syndrome.
pp. 32
[83.]
J. Pantel, K. Machinis, M.L. Sobier, P. Duquesnoy, M. Goossens, S. Amselem.
Species-specific alternative splice mimicry at the qrowth hormone receptor locus revealed by the lineage of retroelements during primate evolution.
J Clin Chem, 275 (2000), pp. 18664-18669
[84.]
M.L. Dattani, J. Martinez-Barbera, P.Q. Thomas, J.M. Brickman, R. Gupta, J.K. Wales, et al.
Molecular genetic of septo-optic dysplasia.
Horm Res, 53 (2000), pp. 26-33
[85.]
L. Pasquier, C. Dubourg, M. Blayau, L. Lazaro, B. Le Marec, V. David, et al.
A new mutation in the six-domain of SIX3 gene causes holoprosencephaly.
Eur J Hum Genet, 8 (2000), pp. 797-800
[86.]
L. Loidi, C. Quinteiro, J. Barreiro, J.M. Cabezas Agricola, F. Dominguez, M. Pombo.
Sequencing the entire CYP21B gene allows the identification of five novel mutations.
Horm Res, 58 (2002), pp. 178
[87.]
A. Penalva, R. Baldelli, J.P. Camina, A.L. Cerro, D. Micic, G. Tamburrano, et al.
Physiology and possible pathology of growth hormone secretagogues.
J Pediatr Endocrinol Metab, 14 (2001), pp. 1207-1212
[88.]
J.A. Janssen, F.M. van der Toorn, L.J. Hofland, P. van Koetsveld, F. Broglio, E. Ghigo, et al.
Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy.
Eur J Endocrinol, 145 (2001), pp. 711-716
Copyright © 2003. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos